Phase I Clinical Trial with a Novel Altered Peptide Ligand Derived from Human Heat-Shock Protein 60 for Treatment of Rheumatoid Arthritis: Safety, Pharmacokinetics and Preliminary Therapeutic Effects

Leonardo Oramas², Maria Del Carmen Domínguez Horta^2*, Gabriel Padrón², Luis Javier González², Vladimir Besada², Cabal Carlos², Alfredo Hernández⁴, Yolanda Cruz⁴, Osvaldo Reyes², Matilde López², Ever Pérez², Hilda Garay², Yassel Ramos², Yaysel Miñoso⁴, Dinorah Prada¹, Osmel Martinez¹, Claudio Molinero¹, Lina Pérez¹, Yisel Avila³, Yuliet Bermudez³, Yusimy Reyes¹, Ania Cabrales², Evelio González², Ana López¹, Oreste Corrales², Norailys Lorenzo² and Jorge Gómez¹

¹National Reference Center for Rheumatic Disease, 10 de Octubre, Havana, Cuba, E-mail: mcarmen.dominguez@cigb.edu.cu

²Center for Genetic Engineering and Biotechnology (CIGB), 6162, Havana, Cuba, E-mail: mcarmen.dominguez@cigb.edu.cu

³National Center for Clinical Trial (CENCEC), Miramar, Playa, CP 11300, Havana, Cuba, E-mail: mcarmen.dominguez@cigb.edu.cu

⁴Center for Surgical Medical Research (CIMEQ), Siboney, Playa, Havana, Cuba, E-mail: mcarmen.dominguez@cigb.edu.cu

^*Corresponding Author: Maria Del Carmen Domínguez Horta, Center for Genetic Engineering and Biotechnology (CIGB), 6162, Havana, Cuba, Tel: +53-7-250-4397 Email: